Abbott Laboratories $ABT Shares Purchased by Investors Research Corp

Investors Research Corp raised its position in Abbott Laboratories (NYSE:ABT) by 7,781.2% during the 2nd quarter, Holdings Channel reports. The firm owned 6,305 shares of the healthcare product maker’s stock after acquiring an additional 6,225 shares during the quarter. Investors Research Corp’s holdings in Abbott Laboratories were worth $572,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Cornerstone Financial Management LLC purchased a new stake in Abbott Laboratories during the 4th quarter worth about $25,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth about $25,000. Purpose Unlimited Inc. purchased a new stake in shares of Abbott Laboratories during the fourth quarter worth about $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in shares of Abbott Laboratories in the fourth quarter valued at approximately $26,000. Finally, Abound Financial LLC acquired a new position in shares of Abbott Laboratories in the fourth quarter valued at approximately $26,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ABT. Leerink Partners decreased their target price on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research report on Tuesday, April 21st. Wells Fargo & Company increased their price target on Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Mizuho lowered their price objective on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. Oppenheimer dropped their target price on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Finally, Robert W. Baird began coverage on Abbott Laboratories in a research note on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $118.17.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $110.92 on Thursday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The firm has a market capitalization of $191.93 billion, a price-to-earnings ratio of 35.90, a price-to-earnings-growth ratio of 2.12 and a beta of 0.59. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company has a 50 day moving average price of $96.86 and a 200 day moving average price of $99.73.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. The company had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same period in the previous year, the company earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s payout ratio is 81.55%.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Bank of America issues a Buy rating: The endorsement from Bank of America Securities adds to positive Wall Street sentiment and may support investor confidence in Abbott’s earnings and growth outlook. Abbott Laboratories Receives a Buy from Bank of America Securities
• Positive Sentiment: Abbott and Google expand glucose-monitoring partnership: Abbott will integrate Lingo glucose data with Google’s AI-driven consumer health tools. The companies also plan a large real-world metabolic-health study, potentially improving personalized coaching, supporting future Lingo features and increasing the commercial value of Abbott’s biowearable platform. Abbott Laboratories Ties Lingo Glucose Data to AI Health Tools
• Positive Sentiment: Potential cardiovascular innovation: Abbott’s ongoing PULSE study is evaluating early treatment for atrial fibrillation. Positive results could strengthen Abbott’s electrophysiology portfolio, although the study remains a longer-term catalyst and does not yet establish a commercial benefit. Early AF Treatment on Trial: What Abbott’s PULSE Study Could Mean for Investors
• Neutral Sentiment: Blood-donation campaign returns: Abbott and the Big Ten revived the “We Give Blood” campaign amid a U.S. blood shortage. The initiative enhances Abbott’s public profile and reinforces its healthcare mission, but it is unlikely to have a material near-term effect on earnings. Abbott and Big Ten Bring Back We Give Blood

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.